TOBAM’s Sage Therapeutics SAGE Stock Holding History

TOBAM’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-2,400	Closed	-$69K	–	163
2020 Q1	$69K	Buy	2,400 +1,500	+167%	+$86.9K	0.01%	127
2019 Q4	$65K	Buy	900 +300	+50%	+$36.9K	﹤0.01%	113
2019 Q3	$84K	Buy	600 +100	+20%	+$16.7K	0.01%	110
2019 Q2	$92K	Buy	+500	New	+$85.3K	0.01%	108

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

TOBAM's SAGE Position: Q2 2020 in Review

TOBAM sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 2,400 shares — an estimated $69K sold.

TOBAM first reported a position in SAGE in Q2 2019 and held it in 4 quarters. The position peaked at $92K in Q2 2019. 217 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

TOBAM reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
TOBAM sold 2,400 Sage Therapeutics shares in Q2 2020, an estimated $69K.
TOBAM first reported a position in Sage Therapeutics in Q2 2019 and held it in 4 quarters.
TOBAM's Sage Therapeutics position peaked at $92K in Q2 2019.
217 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on TOBAM's 13F filing for Q2 2020, filed 17 Aug 2020.